Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05826665 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Observational Study to Examine the Procedural and Outcomes of AF Ablation Assisted by STAR Apollo™ Mapping System

StatusRecruiting
PhaseNot specified
Started2023-10-02
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 16, 2024 (before its estimated July 31, 2025 completion). Its status may not reflect the trial's current state.
STAR Apollo Mapping System is an FDA cleared mapping technology that can analyze the signals collected during the ablation procedure on the 3D mapping system and give the physician further insight into the AF activation patterns which may assist them in identifying areas responsible for maintaining Atrial Fibrillation (AF). The STAR Apollo Mapping System system allows clinicians, after treating the Pulmonary Veins (PV), to collect data from the atria during clinical AF procedures using standard FDA cleared catheters and devices. This study aims to examine the impact of the STAR Apollo Mapping System on procedural and acute outcomes in a multicenter observational study.

Amendment record

Amended 3 times since 2023-04-12; most recent filed 2024-10-14. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2024-10-14
Amendment Study Status v3
2023-10-13
Amendment Not Yet RecruitingRecruiting Study Status, Contacts/Locations v2
2023-04-24
Amendment Study Status v1
2023-04-12
Original filing
Trial Details
NCT Number NCT05826665
Lead Sponsor Kansas City Heart Rhythm Research Foundation
Collaborators: Kansas City Heart Rhythm Institute, St. Bernards Medical Center, Sarasota Medical Center
Conditions Persistent Atrial Fibrillation
Enrollment 200 participants
Start Date 2023-10-02
Primary Completion 2025-07-31 (estimated)
Study Completion 2025-07-31 (estimated)
Updated on ClinicalTrials.gov 2024-10-16